{"protocolSection": {"identificationModule": {"nctId": "NCT03186209", "orgStudyIdInfo": {"id": "D3250C00036"}, "secondaryIdInfos": [{"id": "2017-000702-38", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)", "officialTitle": "A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting \u03b22 Agonist in Patients With Uncontrolled Asthma."}, "statusModule": {"statusVerifiedDate": "2024-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-09-07", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2023-01-30", "type": "ACTUAL"}, "completionDateStruct": {"date": "2023-01-30", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-05-19", "studyFirstSubmitQcDate": "2017-06-12", "studyFirstPostDateStruct": {"date": "2017-06-14", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2023-09-14", "resultsFirstSubmitQcDate": "2024-03-28", "resultsFirstPostDateStruct": {"date": "2024-04-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2024-03-28", "lastUpdatePostDateStruct": {"date": "2024-04-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "This is a randomised, double-blind, parallel group, placebo-controlled study designed to evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma receiving medium to high-dose inhaled corticosteroid plus long-acting \u03b22-agonist (ICS-LABA) with or without oral corticosteroids and additional asthma controllers.", "detailedDescription": "Approximately 666 patients will be randomised. Patients will be stratified by country/region, age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1 (\\<300 or \u2265300 cells/\u03bcL).All the patients will be randomised to either placebo or benralizumab (1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8 weeks thereafter."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma,", "Bronchial Diseases,", "Respiratory Tract Diseases,", "Lung Diseases,", "Obstructive Lung Diseases"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 695, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab", "type": "EXPERIMENTAL", "description": "Benralizumab administered subcutaneously", "interventionNames": ["Biological: Benralizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo administered subcutaneously", "interventionNames": ["Biological: Placebo"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Benralizumab", "description": "Benralizumab subcutaneously on study week 0 until study week 40 inclusive.", "armGroupLabels": ["Benralizumab"]}, {"type": "BIOLOGICAL", "name": "Placebo", "description": "Placebo subcutaneously on study week 0 until study week 40 inclusive.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL", "description": "Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups", "timeFrame": "From randomization through Study Week 48"}], "secondaryOutcomes": [{"measure": "Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in total rescue medication use (number of puffs/day)", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in morning PEF", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in evening PEF", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Time to first asthma exacerbation over 48-week treatment period", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Number and percentage of patients with at least one exacerbation over 48-week treatment period", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Number and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Asthma specific health care resource utilization over 48-week treatment period.", "timeFrame": "From randomization through Study Week 48"}, {"measure": "The Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration", "description": "PK trough concentrations at each visit", "timeFrame": "week 0, week 24, week 48"}, {"measure": "The Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline.", "timeFrame": "Pre-treatment until end of 48-week end of treatment"}, {"measure": "Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Percent change from baseline at Week 48 in blood eosinophil levels", "timeFrame": "From randomization through Study Week 48"}], "otherOutcomes": [{"measure": "Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups", "timeFrame": "From randomization through Study Week 48."}, {"measure": "Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)", "timeFrame": "From randomization through Study Week 48"}, {"measure": "Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.", "timeFrame": "From randomization through Study Week 48"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Written informed consent, and assent when applicable for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent\\[s\\]/guardian\\[s\\]) and according to international guidelines and/or applicable local guidelines.\n2. Female and male aged 12 to 75 years, inclusively, at the time of Visit 1. For those patients, who are 17 on the day of Visit 1 but will turn 18 after this day, will be considered an adolescent for the purposes of this trial.\n3. History of physician-diagnosed asthma requiring treatment with medium-to-high dose ICS (\\>250\u03bcg fluticasone propionate dry powder formulation equivalents total daily dose) and a LABA, for at least 6 months prior to Visit 1.\n4. Additional maintenance asthma controller medications that are locally approved in a country for the treatment of asthma (e.g., leukotriene receptor antagonists (LTRAs), tiotropium, chromone, theophylline, oral corticosteroid), and have been used for at least 30 days prior to Visit 1 are allowed.\n5. At least 2 documented asthma exacerbations in the 12 months prior to the date informed consent, and assent when available, during the treatment of medium-to-high dose ICS-LABA that required use of a systemic corticosteroid or a temporary increase from the patient's usual maintenance dose of oral corticosteroid. For patients who are re-screened within 30 days of their screen failure date, the calculation of the 12 month period should be done from the original informed consent, and assent when applicable date.\n6. Documented post-bronchodilator (post-BD) reversibility in FEV1 of \\>12% and \\>200 mL in FEV1 within 12 months prior to Visit 1. If historical documentation is not available, reversibility must be demonstrated and documented at Visit 2.\n7. Fulfilment of at least 1 of the following conditions over the 7 days prior to randomization:\n\n   * \\>2 days with a daytime or night time symptoms score \\>1\n   * Rescue Short-acting \u03b22 agonist (SABA) use on \\>2 days\n   * \u22651 nocturnal awakening due to asthma\n8. Pre-bronchodilator (Pre-BD) FEV1 of \\<80% predicted (\\<90% predicted for patients aged 12 to 17 years) at Visit 2.\n9. ACQ-6 score \\> = 1.5 at Visit 2.\n\nExclusion Criteria:\n\n1. Known history of clinically important pulmonary disease other than asthma (e.g., active lung infection, chronic obstructive pulmonary disease (COPD), bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g,. allergic bronchopulmonary aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).\n2. Known history of any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could:\n\n   * Affect the safety of the patient throughout the study\n   * Influence the findings of the studies or their interpretations\n   * Impede the patient's ability to complete the entire duration of study.\n3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent, and assent when applicable, is obtained or during the screening period.\n4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study.\n5. Current smokers or former smokers with a smoking history of \\> 10 pack-years.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "75 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Baotou", "zip": "14010", "country": "China", "geoPoint": {"lat": 40.65222, "lon": 109.82222}}, {"facility": "Research Site", "city": "Beijing", "zip": "100020", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Beijing", "zip": "100034", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Beijing", "zip": "100037", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Beijing", "zip": "100050", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Beijing", "zip": "100730", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Changsha", "zip": "410004", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Changsha", "zip": "410015", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Changzhi", "zip": "46000", "country": "China", "geoPoint": {"lat": 35.20889, "lon": 111.73861}}, {"facility": "Research Site", "city": "Chengdu", "zip": "610041", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Research Site", "city": "Chengdu", "zip": "611130", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Research Site", "city": "Chongqing", "zip": "400038", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Research Site", "city": "Foshan", "zip": "528000", "country": "China", "geoPoint": {"lat": 23.02677, "lon": 113.13148}}, {"facility": "Research Site", "city": "Ganzhou", "zip": "341000", "country": "China"}, {"facility": "Research Site", "city": "Guangzhou", "zip": "510080", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Guangzhou", "zip": "510120", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Guangzhou", "zip": "510150", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Guangzhou", "zip": "510180", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Guiyang", "zip": "550004", "country": "China", "geoPoint": {"lat": 26.58333, "lon": 106.71667}}, {"facility": "Research Site", "city": "Haikou", "zip": "570311", "country": "China", "geoPoint": {"lat": 20.04583, "lon": 110.34167}}, {"facility": "Research Site", "city": "Hangzhou", "zip": "310003", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Hangzhou", "zip": "310006", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Hangzhou", "zip": "310009", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Hangzhou", "zip": "310014", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Research Site", "city": "Hohhot", "zip": "010017", "country": "China", "geoPoint": {"lat": 40.81056, "lon": 111.65222}}, {"facility": "Research Site", "city": "Hohhot", "zip": "10050", "country": "China", "geoPoint": {"lat": 40.81056, "lon": 111.65222}}, {"facility": "Research Site", "city": "Jining", "zip": "272029", "country": "China", "geoPoint": {"lat": 35.405, "lon": 116.58139}}, {"facility": "Research Site", "city": "Kunming", "zip": "650032", "country": "China", "geoPoint": {"lat": 25.03889, "lon": 102.71833}}, {"facility": "Research Site", "city": "Kunming", "zip": "650051", "country": "China", "geoPoint": {"lat": 25.03889, "lon": 102.71833}}, {"facility": "Research Site", "city": "Lishui", "zip": "323000", "country": "China", "geoPoint": {"lat": 28.46042, "lon": 119.91029}}, {"facility": "Research Site", "city": "Nanchang", "zip": "330006", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"facility": "Research Site", "city": "Nanjing", "zip": "2100008", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Nanjing", "zip": "210009", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Nanjing", "zip": "210029", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Neijiang", "zip": "641000", "country": "China", "geoPoint": {"lat": 29.58354, "lon": 105.06216}}, {"facility": "Research Site", "city": "Qingdao", "zip": "110016", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "Research Site", "city": "Qingdao", "zip": "266000", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "Research Site", "city": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shanghai", "zip": "200032", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shanghai", "zip": "200072", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shanghai", "zip": "201199", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Research Site", "city": "Shenyang", "zip": "110001", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Shenyang", "zip": "110015", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Research Site", "city": "Taiyuan", "zip": "030001", "country": "China", "geoPoint": {"lat": 37.86944, "lon": 112.56028}}, {"facility": "Research Site", "city": "Taizhou", "zip": "225300", "country": "China", "geoPoint": {"lat": 32.49069, "lon": 119.90812}}, {"facility": "Research Site", "city": "Wanzhou", "zip": "404000", "country": "China"}, {"facility": "Research Site", "city": "Wuhan", "zip": "430030", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Research Site", "city": "Xiangtan", "zip": "411100", "country": "China", "geoPoint": {"lat": 27.85, "lon": 112.9}}, {"facility": "Research Site", "city": "Xinxiang", "zip": "453002", "country": "China", "geoPoint": {"lat": 35.19033, "lon": 113.80151}}, {"facility": "Research Site", "city": "Xuzhou", "zip": "221006", "country": "China", "geoPoint": {"lat": 34.18045, "lon": 117.15707}}, {"facility": "Research Site", "city": "Xuzhou", "zip": "221009", "country": "China", "geoPoint": {"lat": 34.18045, "lon": 117.15707}}, {"facility": "Research Site", "city": "Yangzhou", "zip": "225001", "country": "China", "geoPoint": {"lat": 32.39722, "lon": 119.43583}}, {"facility": "Research Site", "city": "Yinchuan", "zip": "750001", "country": "China", "geoPoint": {"lat": 38.46806, "lon": 106.27306}}, {"facility": "Research Site", "city": "Yinchuan", "zip": "750004", "country": "China", "geoPoint": {"lat": 38.46806, "lon": 106.27306}}, {"facility": "Research Site", "city": "Zhanjiang", "zip": "524001", "country": "China", "geoPoint": {"lat": 21.28145, "lon": 110.34271}}, {"facility": "Research Site", "city": "Zhuhai", "zip": "519099", "country": "China", "geoPoint": {"lat": 22.27694, "lon": 113.56778}}, {"facility": "Research Site", "city": "Zunyi", "zip": "563100", "country": "China", "geoPoint": {"lat": 27.68667, "lon": 106.90722}}, {"facility": "Research Site", "city": "Bucheon-si", "zip": "14584", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "Research Site", "city": "Busan", "zip": "49241", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Research Site", "city": "Cheonan", "zip": "330-715", "country": "Korea, Republic of", "geoPoint": {"lat": 36.8065, "lon": 127.1522}}, {"facility": "Research Site", "city": "Daejeon", "zip": "35365", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Research Site", "city": "Gwangju", "zip": "61469", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Research Site", "city": "Seongnam-si", "zip": "13620", "country": "Korea, Republic of", "geoPoint": {"lat": 37.43861, "lon": 127.13778}}, {"facility": "Research Site", "city": "Seoul", "zip": "03181", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03312", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "04763", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "05505", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "08308", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Suwon-si", "zip": "16499", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "Research Site", "city": "Uijeongbu-si", "zip": "11765", "country": "Korea, Republic of", "geoPoint": {"lat": 37.7415, "lon": 127.0474}}, {"facility": "Research Site", "city": "Wonju", "zip": "26426", "country": "Korea, Republic of", "geoPoint": {"lat": 37.35139, "lon": 127.94528}}, {"facility": "Research Site", "city": "Iloilo City", "zip": "5000", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Research Site", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Research Site", "city": "Taipei", "zip": "100", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "112", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taipei", "zip": "114", "country": "Taiwan", "geoPoint": {"lat": 25.04776, "lon": 121.53185}}, {"facility": "Research Site", "city": "Taoyuan City", "zip": "333", "country": "Taiwan", "geoPoint": {"lat": 24.95233, "lon": 121.20193}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Redacted CSP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=94f140e1-8d12-441f-a36f-47b7a861e52c&amp;fileName=5Sep2023-d3250c00036-csp-v5_Redacted_.pdf&amp;versionIdentifier="}, {"label": "Redacted SAP", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=cc47324b-7f06-401d-a8ed-a6a71fd95944&amp;fileName=d3250c00036-sap-ed3_Redacted_5Sep2023.pdf&amp;versionIdentifier="}, {"label": "Redacted CSR Synopsis", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00036&amp;attachmentIdentifier=2640ddf4-529a-41b1-877d-3d53a0495d8a&amp;fileName=d3250c00036-study-synopsis_Redacted_5Sep2023.pdf&amp;versionIdentifier="}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "infoTypes": ["STUDY_PROTOCOL", "SAP", "CSR"], "timeFrame": "AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "accessCriteria": "When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.", "url": "https://astrazenecagroup-dt.pharmacm.com/DT/Home"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "At the first visit, ie, the enrollment visit 1, participants were evaluated regarding the protocol mandated inclusion and exclusion criteria. After enrollment, eligible participants were randomized to either placebo or Benralizumab 30 mg at a 1:1 ratio, administered subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks thereafter.", "recruitmentDetails": "695 participants were randomized to receive treatment in study D3250C00036 (MIRACLE) with Benralizumab or placebo. All the 695 randomized participants received treatment with study drug.", "groups": [{"id": "FG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "FG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "All Participants Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "348"}, {"groupId": "FG001", "numSubjects": "347"}]}, {"type": "Dosed", "comment": "Full Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "348"}, {"groupId": "FG001", "numSubjects": "347"}]}, {"type": "COMPLETED", "comment": "study", "achievements": [{"groupId": "FG000", "numSubjects": "331"}, {"groupId": "FG001", "numSubjects": "321"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "17"}, {"groupId": "FG001", "numSubjects": "26"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "V18 SKIPPED DUE TO LOGISTICS REASON", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "PI DECIDED TO DISCONTINUE THE STUDY DUE TO THE LACK OF CRC RESOURCES", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Fail to meet randomization criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full analysis set, all participants who were randomized and received at least one investigational product (IP), Benralizumab or Placebo.", "groups": [{"id": "BG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "BG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "348"}, {"groupId": "BG001", "value": "347"}, {"groupId": "BG002", "value": "695"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.1", "spread": "11.56"}, {"groupId": "BG001", "value": "51.0", "spread": "12.56"}, {"groupId": "BG002", "value": "51.1", "spread": "12.06"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": ">=12 - <18 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": ">=18 - <65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "299"}, {"groupId": "BG001", "value": "295"}, {"groupId": "BG002", "value": "594"}]}]}, {"title": ">=65 - <=75", "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "100"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "221"}, {"groupId": "BG001", "value": "207"}, {"groupId": "BG002", "value": "428"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "267"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Non-Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "348"}, {"groupId": "BG001", "value": "347"}, {"groupId": "BG002", "value": "695"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "348"}, {"groupId": "BG001", "value": "347"}, {"groupId": "BG002", "value": "695"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma for Baseline Eosinophils >=300/uL", "description": "Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/patient-year", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.49", "lowerLimit": "0.33", "upperLimit": "0.72"}, {"groupId": "OG001", "value": "1.88", "lowerLimit": "1.35", "upperLimit": "2.61"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Multiplicity protected by hierarchy testing procedure. First in line hypothesis testing, requiring p-value \\<0.05.", "statisticalMethod": "Negative binomial", "statisticalComment": "Model with covariates: treatment group, region (China/Non-China), number of exacerbations in previous year, use of maintenance oral corticosteroids", "paramType": "Rate Ratio", "paramValue": "0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "0.36"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "215"}, {"groupId": "OG001", "value": "204"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.333", "spread": "0.4499"}, {"groupId": "OG001", "value": "0.103", "spread": "0.4841"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Test after significant primary endpoint. Two secondary endpoints (change in FEV1 and total asthma symptom score) using Holm's procedure; smaller p-value to be \\<0.025, and larger p-value to be \\<0.05.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline pre-bronchodilator FEV1, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.17", "ciUpperLimit": "0.34"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Total Asthma Symptom Score for for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "206"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.07", "spread": "1.126"}, {"groupId": "OG001", "value": "-0.80", "spread": "1.129"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0126", "pValueComment": "Test after significant primary endpoint. Two secondary endpoints (change in FEV1 and total asthma symptom score) using Holm's procedure; smaller p-value to be \\<0.025, and larger p-value to be \\<0.05.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline total asthma symptom score, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.45", "ciUpperLimit": "-0.05"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Total Asthma Rescue Medication Use for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in total rescue medication use (number of puffs/day)", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Puffs/day", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "206"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.85", "spread": "1.865"}, {"groupId": "OG001", "value": "-0.89", "spread": "2.213"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1835", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline total asthma rescue medication use, region, use of maintenance oral corticosteroids, visit, treatment\\*visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.42", "ciUpperLimit": "0.08"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Morning Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in morning PEF", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "207"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.194", "spread": "86.3963"}, {"groupId": "OG001", "value": "12.995", "spread": "68.7947"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline morning PEF, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "38.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "24.24", "ciUpperLimit": "53.07"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Evening Peak Expiratory Flow (PEF) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at week 48 in evening PEF", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/min", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "217"}, {"groupId": "OG001", "value": "209"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.661", "spread": "85.4642"}, {"groupId": "OG001", "value": "7.989", "spread": "68.0632"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline evening PEF, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "35.85", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "21.52", "ciUpperLimit": "50.18"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in the Proportion of Night Awakening Due to Asthma and Requiring Rescue Medication for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Change from baseline at Week 48 in proportion of night awakening due to asthma and requiring rescue medication", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Proportion of nights", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "217"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.15", "spread": "0.220"}, {"groupId": "OG001", "value": "-0.15", "spread": "0.260"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.3385", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline proportion of nights awakening, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.01", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.01"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Asthma Control Questionnaire 6 (ACQ-6) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "ACQ-6 contains one bronchodilator question and 5 symptom questions. Questions are rated from 0 (totally controlled) to 6 (severely uncontrolled). Mean ACQ-6 score is the average of the responses.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "218"}, {"groupId": "OG001", "value": "212"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.22", "spread": "0.901"}, {"groupId": "OG001", "value": "-0.79", "spread": "0.962"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline ACQ-6 score, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.58", "ciUpperLimit": "-0.28"}]}, {"type": "SECONDARY", "title": "Time to First Asthma Exacerbation for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Time to first asthma exacerbation over 48-week treatment period", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Days", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "NA", "upperLimit": "NA", "comment": "The number of exacerbations is small, thus the Median survival time to first exacerbation has not reached."}, {"groupId": "OG001", "value": "227", "lowerLimit": "146", "upperLimit": "NA", "comment": "Insufficient number of exacerbations to estimate upper limit of 95% CI."}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Regression, Cox", "statisticalComment": "model including covariates treatment group, region, number of exacerbations in the previous year, and use of maintenance oral corticosteroids", "paramType": "Hazard Ratio (HR)", "paramValue": "0.32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.23", "ciUpperLimit": "0.43"}]}, {"type": "SECONDARY", "title": "Number and Percentage of Patients With >=1 Asthma Exacerbations Among Patients Who Were on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Number and percentage of patients with at least one exacerbation over 48-week treatment period", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "125"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Cochran-Mantel-Haenszel", "statisticalComment": "Controlling for region, number of exacerbations in the previous year (2, \\>=3), use of OCS", "paramType": "Odds Ratio (OR)", "paramValue": "0.28", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.19", "ciUpperLimit": "0.42"}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 48 in Total Score of St. George's Respiratory Questionnaire (SGRQ) for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "The SGRQ is a 50-item PRO instrument developed to measure the HRQoL of patients with airway diseases. The questionnaire is divided into two parts: part 1 consists of 8 items pertaining to the severity of respiratory symptoms in the preceding 4 weeks; part 2 consists of 42 items related to the daily activity and psychosocial impacts of the individual's respiratory condition. The total score indicates the impact of disease on overall HRQoL. This total score is expressed as a percentage of overall impairment, in which 100 represents the worst possible HRQoL and 0 indicates the best possible HRQoL.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "209"}, {"groupId": "OG001", "value": "200"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.24", "spread": "20.509"}, {"groupId": "OG001", "value": "-14.75", "spread": "21.838"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with covariates: treatment group, baseline SGRQ total score, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-9.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.79", "ciUpperLimit": "-5.60"}]}, {"type": "SECONDARY", "title": "Annual Asthma Exacerbation Rate Associated With an Emergency Room/Urgent Care Visit or a Hospitalization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Annual asthma exacerbation rate associated with an emergency room/urgent care visit or a hospitalization over 48-week treatment period", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/patient-year", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "0.04", "upperLimit": "0.11"}, {"groupId": "OG001", "value": "0.14", "lowerLimit": "0.09", "upperLimit": "0.20"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0222", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Negative binomial", "statisticalComment": "Model includes Treatment, use of maintenance oral corticosteroids, categorical variable of ER/UC or hospitalization exacerbations during previous year", "paramType": "Rate ratio", "paramValue": "0.46", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.24", "ciUpperLimit": "0.90"}]}, {"type": "SECONDARY", "title": "Number and Percentages of Asthma Specific Health Care Resource Utilization for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Asthma specific health care resource utilization over 48-week treatment period.", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "236"}, {"groupId": "OG001", "value": "237"}]}], "classes": [{"title": "Hospitalisations", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "21"}]}]}, {"title": "Emergency Department Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}]}]}, {"title": "Unscheduled Outpatient Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "53"}, {"groupId": "OG001", "value": "99"}]}]}, {"title": "Home Visits", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Telephone Calls", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "71"}]}]}, {"title": "Ambulance Transports", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Advanced Pulmonary Function Test", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "8"}]}]}]}, {"type": "SECONDARY", "title": "The Pharmacokinetics (PK) of Benralizumab as Assessed by Trough Concentration", "description": "PK trough concentrations at each visit", "populationDescription": "PK analysis set; number analyzed includes participants with available value at each specified time point.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "week 0, week 24, week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"title": "Week 0", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0", "spread": "0"}]}]}, {"title": "Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "297"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "137.914", "spread": "432.419"}]}]}, {"title": "Week 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "289"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "123.476", "spread": "395.951"}]}]}]}, {"type": "SECONDARY", "title": "The Immunogenicity of Benralizumab as Assessed by the Presence of Anti-drug Antibodies (ADAs)", "description": "Anti-drug antibodies (ADA) responses at baseline and post baseline.", "populationDescription": "Safety analysis set; number analyzed includes participants with available value at each specified time point.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Pre-treatment until end of 48-week end of treatment", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "classes": [{"title": "ADA positive at any time, including baseline and/or post-baseline (ADA prevalence)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Treatment-emergent ADA positive, including treatment-induced and treatment-boosted ADA positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Treatment-induced ADA positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Treatment-boosted ADA positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ADA positive at both baseline and at least one post-baseline assessment", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "ADA positive at baseline only", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "ADA persistently positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "ADA transiently positive", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "ADA positive with maximum titre > median of maximum titres", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "ADA positive with maximum titre <= median of maximum titres", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "4"}]}]}, {"title": "nAb prevalence (nAb positive at any time, including baseline and/or post-baseline)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "348"}, {"groupId": "OG001", "value": "347"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "nAb incidence", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "345"}, {"groupId": "OG001", "value": "336"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "55"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Percent Change From Baseline at Week 48 in Blood Eosinophil Levels for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils >=300/uL", "description": "Percent change from baseline at Week 48 in blood eosinophil levels", "populationDescription": "Full analysis set, Baseline eosinophils \\>=300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percent change", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "213"}, {"groupId": "OG001", "value": "199"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-80.6", "spread": "34.65"}, {"groupId": "OG001", "value": "42.3", "spread": "380.86"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "model includes treatment , baseline eosinophil count, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-119.31", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-169.78", "ciUpperLimit": "-68.84"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Annual Asthma Exacerbation Rate in Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Annual asthma exacerbation rate over the 48-week treatment period among benralizumab and placebo groups", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/patient-year", "timeFrame": "From randomization through Study Week 48.", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "112"}, {"groupId": "OG001", "value": "110"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.72", "lowerLimit": "0.49", "upperLimit": "1.06"}, {"groupId": "OG001", "value": "0.87", "lowerLimit": "0.61", "upperLimit": "1.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.4519", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Negative binomial", "statisticalComment": "Model with covariates: treatment group, region (China/Non-China), number of exacerbations in previous year, use of maintenance oral corticosteroids", "paramType": "Rate Ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.51", "ciUpperLimit": "1.35"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline at Week 48 in Pre-bronchodilator FEV1 (L) Value for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Change from baseline at Week 48 in Pre-bronchodilator FEV1 (L)", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liter", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "97"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.178", "spread": "0.4068"}, {"groupId": "OG001", "value": "0.045", "spread": "0.3626"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0214", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline pre-bronchodilator FEV1, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.02", "ciUpperLimit": "0.22"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline at Week 48 in Total Asthma Symptom Score for Patients on Medium to High-dose ICS-LABA With Uncontrolled Asthma and Baseline Eosinophils <300/uL", "description": "Daytime and nighttime symptoms are reported using a response scale ranging from 0 to 3 where 0 indicates no asthma symptoms. The total asthma symptom score is the sum of the daytime and nighttime scores and ranges from 0 to 6; a decrease in score indicates symptom improvement.", "populationDescription": "Full analysis set, Baseline eosinophils \\<300/uL; number analyzed refers to records with value available at Week 48 for this outcome measure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Scores on a scale", "timeFrame": "From randomization through Study Week 48", "groups": [{"id": "OG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously"}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.97", "spread": "1.260"}, {"groupId": "OG001", "value": "-0.75", "spread": "1.105"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.1589", "pValueComment": "Nominal p-value. Not multiplicity protected by testing procedure.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model includes Treatment, baseline total asthma symptom score, region, use of maintenance oral corticosteroids, visit, and treatment by visit", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.51", "ciUpperLimit": "0.08"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From initial dose of the study treatment to the end of study, i.e., up to 56 weeks of follow-up.", "description": "All treated participants from the first dose to the end of study. Total of 695 participants with 348 participants treated with Benralizumab administered every 4 weeks for the first 3 doses and then every 8 weeks and 347 were under placebo treatment.", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30 mg", "description": "Benralizumab administered subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 348, "seriousNumAffected": 44, "seriousNumAtRisk": 348, "otherNumAffected": 194, "otherNumAtRisk": 348}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 347, "seriousNumAffected": 63, "seriousNumAtRisk": 347, "otherNumAffected": 194, "otherNumAtRisk": 347}], "seriousEvents": [{"term": "Arteriosclerosis coronary artery", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Reflux gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cholecystitis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Hepatic mass", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Food allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Asymptomatic COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Bronchopulmonary aspergillosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Bronchopulmonary aspergillosis allergic", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 347}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Pelvic infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 347}]}, {"term": "Pneumonia bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 347}]}, {"term": "Pneumonia pneumococcal", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Pulmonary tuberculosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Femoral neck fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Fibromyalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 347}]}, {"term": "Osteoarthropathy", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Osteoporosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Periarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Tendonitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Adenolymphoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Intraductal papilloma of breast", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Ovarian adenoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Ovarian germ cell teratoma benign", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 347}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cerebral ischaemia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Renal mass", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Uterine polyp", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Uterine prolapse", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 12, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 37, "numAffected": 33, "numAtRisk": 347}]}, {"term": "Bronchiectasis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Lung opacity", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Sinus polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Vocal cord polyp", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Arteriosclerosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Neurogenic shock", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 347}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Chronic gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Duodenitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Enteritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Gastritis erosive", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 347}]}, {"term": "Irritable bowel syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 347}]}], "otherEvents": [{"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 22, "numAffected": 18, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 347}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 15, "numAffected": 11, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 40, "numAffected": 27, "numAtRisk": 347}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 347}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 36, "numAffected": 28, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 48, "numAffected": 33, "numAtRisk": 347}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 347}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 13, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 347}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 9, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 19, "numAffected": 16, "numAtRisk": 347}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 14, "numAffected": 13, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 9, "numAffected": 6, "numAtRisk": 347}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 200, "numAffected": 120, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 230, "numAffected": 120, "numAtRisk": 347}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 9, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 347}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 11, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 14, "numAffected": 8, "numAtRisk": 347}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 41, "numAffected": 22, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 17, "numAffected": 15, "numAtRisk": 347}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 25.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 348}, {"groupId": "EG001", "numEvents": 14, "numAffected": 13, "numAtRisk": 347}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Institution and/or the Principal Investigator shall not include in or shall remove from any proposed publication any Confidential Information, errors or inaccuracies; and shall withhold publication, submission for publication or presentation for a period of ninety (90) days from the date on which the Company receives the material to allow the Company to take such measures as the Company considers necessary to preserve its proprietary rights and/or protect its Confidential Information."}, "pointOfContact": {"title": "Global Clinical Head", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "1-877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-12-18", "uploadDate": "2023-09-14T11:20", "filename": "Prot_000.pdf", "size": 12322085}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2023-01-31", "uploadDate": "2023-09-14T11:21", "filename": "SAP_001.pdf", "size": 2098514}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2023-10-10", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}